401 related articles for article (PubMed ID: 8988048)
1. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
King HD; Yurgaitis D; Willner D; Firestone RA; Yang MB; Lasch SJ; Hellström KE; Trail PA
Bioconjug Chem; 1999; 10(2):279-88. PubMed ID: 10077478
[TBL] [Abstract][Full Text] [Related]
6. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.
Sivam GP; Martin PJ; Reisfeld RA; Mueller BM
Cancer Res; 1995 Jun; 55(11):2352-6. PubMed ID: 7757986
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of CC49-doxorubicin immunoconjugates.
Johnson DA; Briggs SL; Gutowski MC; Barton R
Anticancer Res; 1995; 15(4):1387-93. PubMed ID: 7654026
[TBL] [Abstract][Full Text] [Related]
9. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates.
Carcenac M; Larroque C; Langlois R; van Lier JE; Artus JC; Pèlegrin A
Photochem Photobiol; 1999 Dec; 70(6):930-6. PubMed ID: 10628305
[TBL] [Abstract][Full Text] [Related]
10. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
[TBL] [Abstract][Full Text] [Related]
11. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
12. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
13. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
14. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
Takahashi H; Adachi K; Yamaguchi F; Teramoto A
Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
[TBL] [Abstract][Full Text] [Related]
15. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
16. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
17. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
